{
    "clinical_study": {
        "@rank": "122753", 
        "arm_group": {
            "arm_group_label": "chemotherapy plus bevacizumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A phase II Study of an adapted chemotherapy regimen plus bevacizumab in elderly non-small\n      cell lung cancer patients selected by geriatric assessment"
        }, 
        "brief_title": "A Phase II Study of Chemotherapy Regimen Plus Bevacizumab in Elderly Non-small Cell Lung Cancer (NSCLC) Patients Selected by Geriatric Assessment", 
        "condition": "Non-small Cell Lung Cancer (NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent confirming that the patient understands the study objective\n             and the procedures required.\n\n          -  Patients must be able to accomplish with the study protocol.\n\n          -  Men and women \u226570 years old.\n\n          -  Histologically or cytologically confirmed diagnosis of non-squamous non-small cell\n             lung cancer (NSCLC) with EGFR gen mutational status negative or non-determinable.\n\n          -  Patients with stage IV disease.\n\n          -  Patients who have not received first-line treatment\n\n          -  Patients with ECOG performance status 0 or 1.\n\n          -  Adequate bone marrow function, defined as:\n\n        Absolute neutrophil count (ANC)  \u22651.500/mm3 or \u22651.5x109/L; Hemoglobin \u2265 9 g/dL. Platelet\n        count \u2265 100.000/mm3. \u2022 Adequate renal function, defined as: Creatinine clearance \u2265 40\n        ml/min, according to MDRD formula. Urine dipstick proteinuria <2+. If urine dipstick for\n        proteinuria \u22652+ 24 hours urine must be collected within 24 hours, and proteins must be\n        less than 1 g.\n\n        \u2022 Fertile males must use an effective contraceptive method (error rate per year <1%)\n        during the trial and until 6 months after the last study treatment dose, such as sexual\n        abstinence, previous vasectomy and/or having a partner using any of following methods:\n        implantables, injections, combined oral contraceptives and/or intrauterine device\n        (hormonal only).\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy for advanced NSCLC.\n\n          -  History of haemoptysis grade \u2265 2 (defined as at least 2.5 mL of bright red blood) in\n             the 3 months before inclusion.\n\n          -  Major surgery (including open biopsy), significant traumatic injuries in the 28 days\n             before inclusion or anticipation of the need of major surgical procedure during the\n             treatment period\n\n          -  Minor surgery, including permanent catheter insertion, in the 24 hours before\n             bevacizumab infusion.\n\n          -  Untreated brain metastases. Patients with CNS metastases treated with radiotherapy or\n             surgery may be included if there is no evidence of progression after treatment\n\n          -  Radiological evidence of a tumor that invades or is adjacent to a main blood vessel\n             (e.g. lung artery or superior cava venous).\n\n          -  Radiotherapy, in any lesion and for any reason, within 28 days before inclusion.\n             Palliative radiotherapy for bone lesions within 14 days before inclusion is allowed.\n\n          -  Treatment with aspirin (>325 mg/day) or clopidogrel (>75 mg/day) within 10 days prior\n             to bevacizumab first dose. Use of full dose of oral or parenteral anticoagulants or\n             thrombolytic agents in therapeutic doses. Prophylactic use of anticoagulant therapy\n             is allowed.\n\n          -  Uncontrolled hypertension (systolic BP >140 mmHg, diastolic BP >90mmHg) in the 28\n             days previous to inclusion or history of hypertensive crisis , or hypertensive\n             encephalopathy.\n\n          -  Clinically significant cardiovascular disease (i.e. cerebrovascular accident (CVA),\n             myocardial infarction within 6 months prior to inclusion, unstable angina, congestive\n             cardiac insufficiency NYHA \u2265 II, left ventricular ejection fraction (LVEF) <50%  or\n             serious cardiac arrhythmia), not responding to treatment or that can interfere with\n             trial treatment administration.\n\n          -  Not healed wounds, active peptic ulcer or untreated bone fracture.\n\n          -  Hypersensibility to any of the active ingredients of the study treatment\n             (bevacizumab, carboplatine and paclitaxel) or  any of its excipients.\n\n          -  Serious cognitive impairment that limits the patient to understand and answer the\n             study questionnaires.\n\n          -  Inability to comply with the study protocol and/or follow-up procedures due to\n             psychological, familiar, social or geographical problems\n\n          -  Patients with an ADL score <5 at the screening.\n\n          -  Patients with dementia: 9-12 points in the Folstein MMS at the screening.\n\n          -  Patients accomplishing fragility Balducci criteria at the screening:\n\n        Age \u2265 85 years old Dependence in 1 or more ADL >3 comorbidities >1 geriatric syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980472", 
            "org_study_id": "GIDO1201"
        }, 
        "intervention": {
            "arm_group_label": "chemotherapy plus bevacizumab", 
            "description": "4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity", 
            "intervention_name": "bevacizumab, carboplatin and paclitaxel", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 4, 2013", 
        "link": {
            "url": "http://www.gido.es"
        }, 
        "location": [
            {
                "contact": {
                    "email": "quicoaparisi@hotmail.com", 
                    "last_name": "Francisco Aparisi"
                }, 
                "facility": {
                    "address": {
                        "city": "Alcoy", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "03804"
                    }, 
                    "name": "Hospital Virgen de los Lirios"
                }, 
                "investigator": {
                    "last_name": "Francisco Aparisi, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "asanchez@seom.org", 
                    "last_name": "Alfredo S\u00e1nchez"
                }, 
                "facility": {
                    "address": {
                        "city": "Castell\u00f3n", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "12002"
                    }, 
                    "name": "Hospital de Castell\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Alfredo S\u00e1nchez, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marllorent@hotmail.com", 
                    "last_name": "Mar Llorente"
                }, 
                "facility": {
                    "address": {
                        "city": "Elda", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "03600"
                    }, 
                    "name": "Hospital de Elda"
                }, 
                "investigator": {
                    "last_name": "Mar Llorente, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jvicent@hospitalmanises.es", 
                    "last_name": "Jose M Vicent"
                }, 
                "facility": {
                    "address": {
                        "city": "Manises", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "46940"
                    }, 
                    "name": "Hospital de Manises"
                }, 
                "investigator": {
                    "last_name": "Jose M Vicent, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "davidalbalat@hotmail.com", 
                    "last_name": "David Balaguer"
                }, 
                "facility": {
                    "address": {
                        "city": "Sagunto", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "46520"
                    }, 
                    "name": "Hospital de Sagunto"
                }, 
                "investigator": {
                    "last_name": "David Balaguer, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "aljimenez73@hotmail.com", 
                    "last_name": "Antonio L\u00f3pez"
                }, 
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "03550"
                    }, 
                    "name": "Hospital San Juan"
                }, 
                "investigator": {
                    "last_name": "Antonio L\u00f3pez, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "juan_osc@gva.es", 
                    "last_name": "Oscar Juan"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital U. y P. La Fe"
                }, 
                "investigator": {
                    "last_name": "Oscar Juan, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "girones_reg@gva.es", 
                    "last_name": "Regina Girones"
                }, 
                "facility": {
                    "address": {
                        "city": "X\u00e1tiva", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "46800"
                    }, 
                    "name": "Hospital Lluis Alcanyis"
                }, 
                "investigator": {
                    "last_name": "Regina Girones, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (\u2265 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of grade 3-4 neutropenia defined according to National Cancer Institute Common Terminology Criteria version 4.0 (NCI-CTC v4.0)", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of the study, around 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma VEGF", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of the study, around 3 years"
            }, 
            {
                "measure": "Objective response and Stable disease according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of the study, around 3 years"
            }, 
            {
                "measure": "progression-free survival and overall survival", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of the study, around 3 years"
            }
        ], 
        "source": "Grupo de Investigaci\u00f3n y Divulgaci\u00f3n Oncol\u00f3gica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grupo de Investigaci\u00f3n y Divulgaci\u00f3n Oncol\u00f3gica", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}